18552478. ENHANCING T CELL FUNCTION THROUGH THE USE OF PROXIMAL SIGNALING MOLECULES simplified abstract (The Board of Trustees of the Leland Stanford Junior University)
Contents
- 1 ENHANCING T CELL FUNCTION THROUGH THE USE OF PROXIMAL SIGNALING MOLECULES
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 ENHANCING T CELL FUNCTION THROUGH THE USE OF PROXIMAL SIGNALING MOLECULES - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Original Abstract Submitted
ENHANCING T CELL FUNCTION THROUGH THE USE OF PROXIMAL SIGNALING MOLECULES
Organization Name
The Board of Trustees of the Leland Stanford Junior University
Inventor(s)
Robbie G. Majzner of Palo Alto CA (US)
Aidan Tousley of Stanford CA (US)
Maria Caterina Rotiroti of Stanford CA (US)
ENHANCING T CELL FUNCTION THROUGH THE USE OF PROXIMAL SIGNALING MOLECULES - A simplified explanation of the abstract
This abstract first appeared for US patent application 18552478 titled 'ENHANCING T CELL FUNCTION THROUGH THE USE OF PROXIMAL SIGNALING MOLECULES
Simplified Explanation
The present disclosure is about an isolated recombinant cell that overexpresses a SLP-76 polypeptide, along with compositions and methods for producing these cells and corresponding SLP-76 molecules. It also includes methods for treating diseases like cancer with these compositions.
- Isolated recombinant cell overexpressing a SLP-76 polypeptide
- Compositions and methods for producing the isolated recombinant cells and SLP-76 molecules
- Methods for treating diseases, such as cancer, with these compositions
Potential Applications
The technology can be used in the development of new treatments for diseases like cancer by targeting SLP-76.
Problems Solved
This technology addresses the need for more effective treatments for diseases like cancer by utilizing isolated recombinant cells that overexpress SLP-76.
Benefits
The benefits of this technology include potentially improved treatment options for diseases like cancer, as well as the ability to target specific cellular pathways for therapeutic purposes.
Potential Commercial Applications
One potential commercial application of this technology could be the development of novel therapies for cancer treatment, which could have significant market potential.
Possible Prior Art
Prior art may include research on SLP-76 and its role in cellular signaling pathways, as well as studies on recombinant cell technology for therapeutic applications.
Unanswered Questions
How does the overexpression of SLP-76 in isolated recombinant cells specifically impact cancer treatment?
The article does not delve into the specific mechanisms by which overexpressing SLP-76 in isolated recombinant cells can lead to improved cancer treatment outcomes.
Are there any potential side effects or limitations associated with using isolated recombinant cells overexpressing SLP-76 for disease treatment?
The potential drawbacks or limitations of this technology, such as off-target effects or immune responses, are not discussed in the article.
Original Abstract Submitted
The present disclosure generally relates to, inter alia, an isolated recombinant cell overexpressing a SLP-76 polypeptide. The disclosure also provides compositions and methods useful for producing the isolated recombinant cells and the corresponding SLP-76 molecules, as well as methods for treatment of diseases, such as cancer, with such compositions.
